ArticleJournal of clinical medicine2023

Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma.

Rosemary Noel Senguttuvan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.